Posted 2 weeks ago

JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).

ClinicalTrials.gov ID NCT02609776

Protocol number JNJ-61186372

Sponsor Janssen Research & Development, LLC